CellBio Scientific, a leading global provider of advanced tools and services for biomedical research and preclinical discovery, is excited to announce the appointment of Charles Miller as Chief Executive Officer, effective March 31, 2025. Dr. Miller will lead the company's growth following recent strategic acquisitions and spearhead efforts to scale the business, deepen market impact, and unlock new customer value across life sciences research and drug discovery.
"I'm honored to join CellBio Scientific at such a pivotal moment in its journey," said Miller. "The opportunity to unify exceptional teams, build on a foundation of scientific excellence, and scale solutions that truly advance human health is both exciting and urgent. I look forward to working closely with our customers, partners, and employees to drive innovation, unlock new markets, and shape the future of drug discovery and human health."
Miller holds a BS and PhD in biomedical sciences from The University of Michigan and Michigan State University, respectively, and an MBA from Yale. His management style is characterized by clarity, resilience, and a commitment to building high-performance cultures that deliver measurable impact.
"Charles is exactly the leader we need to drive CellBio Scientific into its next phase of growth," said Mark Hilderbrand, CellBio Board of Directors Chair and Housatonic Partners Managing Director. "His experience scaling global life sciences platforms, coupled with a deep scientific understanding and a bold vision for innovation, makes him uniquely suited to lead this business forward. Under his leadership, we are confident CellBio will continue to deliver exceptional value to its customers and investors."
Comments powered by CComment